Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial


Ray K. K. , Colhoun H. M. , Szarek M., Baccara-Dinet M., Bhatt D. L. , Bittner V. A. , ...More

LANCET DIABETES & ENDOCRINOLOGY, vol.7, pp.618-628, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 7 Issue: 8
  • Publication Date: 2019
  • Doi Number: 10.1016/s2213-8587(19)30158-5
  • Title of Journal : LANCET DIABETES & ENDOCRINOLOGY
  • Page Numbers: pp.618-628

Abstract

Background After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1.4-1.8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome is unknown. We aimed to explore this issue in a prespecified analysis of the ODYSSEY OUTCOMES trial of the PCSK9 inhibitor alirocumab, assessing its effects on cardiovascular outcomes by baseline glycaemic status, while also assessing its effects on glycaemic measures including risk of new-onset diabetes.